{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set","reportingStatus":"POSTED","timeFrame":"9 months after the last participant is randomized or later to data cut off, up to approximately 35 months","title":"The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors","type":"SECONDARY","unitOfMeasure":"Participants"}